CA2692973A1 - Selection de patient et procedes therapeutiques utilisant des marqueurs du metabolisme de la prostaglandine - Google Patents
Selection de patient et procedes therapeutiques utilisant des marqueurs du metabolisme de la prostaglandine Download PDFInfo
- Publication number
- CA2692973A1 CA2692973A1 CA 2692973 CA2692973A CA2692973A1 CA 2692973 A1 CA2692973 A1 CA 2692973A1 CA 2692973 CA2692973 CA 2692973 CA 2692973 A CA2692973 A CA 2692973A CA 2692973 A1 CA2692973 A1 CA 2692973A1
- Authority
- CA
- Canada
- Prior art keywords
- subject
- level
- cox
- therapy
- selective inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000002560 therapeutic procedure Methods 0.000 title claims description 785
- 150000003180 prostaglandins Chemical class 0.000 title claims description 23
- 230000004060 metabolic process Effects 0.000 title description 4
- 238000010187 selection method Methods 0.000 title description 2
- 238000000034 method Methods 0.000 claims abstract description 914
- 238000011282 treatment Methods 0.000 claims abstract description 309
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 143
- 201000011510 cancer Diseases 0.000 claims abstract description 126
- 206010061218 Inflammation Diseases 0.000 claims abstract description 8
- 208000002193 Pain Diseases 0.000 claims abstract description 8
- 230000004054 inflammatory process Effects 0.000 claims abstract description 8
- 229940111134 coxibs Drugs 0.000 claims description 795
- 239000012472 biological sample Substances 0.000 claims description 631
- 150000001875 compounds Chemical class 0.000 claims description 584
- CUJMXIQZWPZMNQ-XYYGWQPLSA-N 13,14-dihydro-15-oxo-prostaglandin E2 Chemical compound CCCCCC(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O CUJMXIQZWPZMNQ-XYYGWQPLSA-N 0.000 claims description 530
- 239000003795 chemical substances by application Substances 0.000 claims description 524
- 239000000523 sample Substances 0.000 claims description 451
- 150000003166 prostaglandin E2 derivatives Chemical class 0.000 claims description 308
- ZZDIPNSMKJPHTR-UHFFFAOYSA-N 1,2-diphenylpyrrole Chemical class C=1C=CC=CC=1N1C=CC=C1C1=CC=CC=C1 ZZDIPNSMKJPHTR-UHFFFAOYSA-N 0.000 claims description 289
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims description 286
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 claims description 280
- JTMITOKKUMVWRT-UHFFFAOYSA-N apricoxib Chemical compound C1=CC(OCC)=CC=C1C1=CC(C)=CN1C1=CC=C(S(N)(=O)=O)C=C1 JTMITOKKUMVWRT-UHFFFAOYSA-N 0.000 claims description 279
- 230000014509 gene expression Effects 0.000 claims description 121
- 230000009467 reduction Effects 0.000 claims description 50
- ZJAZCYLYLVCSNH-JHJVBQTASA-N prostaglandin E2-UM Chemical compound O[C@@H]1CC(=O)[C@H](CCC(O)=O)[C@H]1CCC(=O)CCCCC(O)=O ZJAZCYLYLVCSNH-JHJVBQTASA-N 0.000 claims description 44
- 210000002700 urine Anatomy 0.000 claims description 38
- 230000004044 response Effects 0.000 claims description 35
- 230000007423 decrease Effects 0.000 claims description 32
- 206010006187 Breast cancer Diseases 0.000 claims description 31
- 208000026310 Breast neoplasm Diseases 0.000 claims description 31
- 239000003814 drug Substances 0.000 claims description 26
- 229940124597 therapeutic agent Drugs 0.000 claims description 26
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims description 24
- 239000002243 precursor Substances 0.000 claims description 24
- 230000000694 effects Effects 0.000 claims description 23
- 206010060862 Prostate cancer Diseases 0.000 claims description 20
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 20
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 20
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 20
- 102000010825 Actinin Human genes 0.000 claims description 18
- 108010063503 Actinin Proteins 0.000 claims description 18
- 206010009944 Colon cancer Diseases 0.000 claims description 17
- 230000003247 decreasing effect Effects 0.000 claims description 16
- 206010033128 Ovarian cancer Diseases 0.000 claims description 15
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 15
- 206010005003 Bladder cancer Diseases 0.000 claims description 14
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 14
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 14
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 14
- 239000013610 patient sample Substances 0.000 claims description 13
- JWICNZAGYSIBAR-LEEGLKINSA-N (4s)-4-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-5-[[2-[[(2s)-3-carboxy-1-[[(2s)-1-[[1-[[(2s)-1-[[(2s)-4-carboxy-1-[[2-[[2-[[2-[[(2s)-1-[[(1s)-1-carboxy-4-(diaminomethylideneamino Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)C(CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)N)CC1=CC=CC=C1 JWICNZAGYSIBAR-LEEGLKINSA-N 0.000 claims description 12
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 12
- 102000004121 Annexin A5 Human genes 0.000 claims description 12
- 108090000672 Annexin A5 Proteins 0.000 claims description 12
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 12
- 108010077840 Complement C3a Proteins 0.000 claims description 12
- 101100339887 Drosophila melanogaster Hsp27 gene Proteins 0.000 claims description 12
- 102400000525 Fibrinopeptide A Human genes 0.000 claims description 12
- 101800000974 Fibrinopeptide A Proteins 0.000 claims description 12
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims description 12
- 101150096895 HSPB1 gene Proteins 0.000 claims description 12
- 102100034523 Histone H4 Human genes 0.000 claims description 12
- 108010033040 Histones Proteins 0.000 claims description 12
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 12
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 12
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 12
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 12
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 12
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 12
- 201000009030 Carcinoma Diseases 0.000 claims description 11
- 208000023747 urothelial carcinoma Diseases 0.000 claims description 11
- 201000003444 follicular lymphoma Diseases 0.000 claims description 10
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 9
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 9
- 201000002528 pancreatic cancer Diseases 0.000 claims description 9
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 9
- 102100027211 Albumin Human genes 0.000 claims description 8
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 8
- 101100001390 Homo sapiens ALB gene Proteins 0.000 claims description 8
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 8
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 8
- 201000004101 esophageal cancer Diseases 0.000 claims description 8
- 230000002485 urinary effect Effects 0.000 claims description 8
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 7
- -1 SPARC Proteins 0.000 claims description 7
- 210000002966 serum Anatomy 0.000 claims description 7
- 108700020469 14-3-3 Proteins 0.000 claims description 6
- 102000004899 14-3-3 Proteins Human genes 0.000 claims description 6
- 102000009091 Amyloidogenic Proteins Human genes 0.000 claims description 6
- 108010048112 Amyloidogenic Proteins Proteins 0.000 claims description 6
- 102000004145 Annexin A1 Human genes 0.000 claims description 6
- 108090000663 Annexin A1 Proteins 0.000 claims description 6
- 102100034618 Annexin A3 Human genes 0.000 claims description 6
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims description 6
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims description 6
- 102100037320 Apolipoprotein A-IV Human genes 0.000 claims description 6
- 108010071619 Apolipoproteins Proteins 0.000 claims description 6
- 102000007592 Apolipoproteins Human genes 0.000 claims description 6
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 6
- 206010055113 Breast cancer metastatic Diseases 0.000 claims description 6
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 claims description 6
- 108010075016 Ceruloplasmin Proteins 0.000 claims description 6
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 6
- 108010072220 Cyclophilin A Proteins 0.000 claims description 6
- 102100031655 Cytochrome b5 Human genes 0.000 claims description 6
- 108010007167 Cytochromes b5 Proteins 0.000 claims description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 6
- 102000030914 Fatty Acid-Binding Human genes 0.000 claims description 6
- 108010049003 Fibrinogen Proteins 0.000 claims description 6
- 102000008946 Fibrinogen Human genes 0.000 claims description 6
- 102100028313 Fibrinogen beta chain Human genes 0.000 claims description 6
- 101710170765 Fibrinogen beta chain Proteins 0.000 claims description 6
- 101710122170 Glutamate dehydrogenase 1 Proteins 0.000 claims description 6
- 102100034009 Glutamate dehydrogenase 1, mitochondrial Human genes 0.000 claims description 6
- 102000005623 HSP27 Heat-Shock Proteins Human genes 0.000 claims description 6
- 108010045100 HSP27 Heat-Shock Proteins Proteins 0.000 claims description 6
- 102000014702 Haptoglobin Human genes 0.000 claims description 6
- 108050005077 Haptoglobin Proteins 0.000 claims description 6
- 102100021519 Hemoglobin subunit beta Human genes 0.000 claims description 6
- 108091005904 Hemoglobin subunit beta Proteins 0.000 claims description 6
- 108010054147 Hemoglobins Proteins 0.000 claims description 6
- 102000001554 Hemoglobins Human genes 0.000 claims description 6
- 102000013271 Hemopexin Human genes 0.000 claims description 6
- 108010026027 Hemopexin Proteins 0.000 claims description 6
- 101710185235 High mobility group protein 1 Proteins 0.000 claims description 6
- 102100037907 High mobility group protein B1 Human genes 0.000 claims description 6
- 101710168537 High mobility group protein B1 Proteins 0.000 claims description 6
- 101000924454 Homo sapiens Annexin A3 Proteins 0.000 claims description 6
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 claims description 6
- 101000990912 Homo sapiens Matrilysin Proteins 0.000 claims description 6
- 101001023833 Homo sapiens Neutrophil gelatinase-associated lipocalin Proteins 0.000 claims description 6
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 6
- 101000773122 Homo sapiens Thioredoxin domain-containing protein 5 Proteins 0.000 claims description 6
- 101000781865 Homo sapiens Zinc finger CCCH domain-containing protein 7B Proteins 0.000 claims description 6
- 102100029620 Immunoglobulin lambda constant 2 Human genes 0.000 claims description 6
- 108010004020 Immunoglobulin lambda-Chains Proteins 0.000 claims description 6
- 102000003855 L-lactate dehydrogenase Human genes 0.000 claims description 6
- 108700023483 L-lactate dehydrogenases Proteins 0.000 claims description 6
- 102100030417 Matrilysin Human genes 0.000 claims description 6
- 102100026784 Myelin proteolipid protein Human genes 0.000 claims description 6
- 101710094913 Myelin proteolipid protein Proteins 0.000 claims description 6
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims description 6
- 102100031903 Neudesin Human genes 0.000 claims description 6
- 101710090805 Neudesin Proteins 0.000 claims description 6
- 102100035405 Neutrophil gelatinase-associated lipocalin Human genes 0.000 claims description 6
- 108010035916 Nuclear Matrix-Associated Proteins Proteins 0.000 claims description 6
- 102000008297 Nuclear Matrix-Associated Proteins Human genes 0.000 claims description 6
- 102100036961 Nuclear mitotic apparatus protein 1 Human genes 0.000 claims description 6
- 102100034539 Peptidyl-prolyl cis-trans isomerase A Human genes 0.000 claims description 6
- 102100027184 Periplakin Human genes 0.000 claims description 6
- 101710202907 Periplakin Proteins 0.000 claims description 6
- 102000007456 Peroxiredoxin Human genes 0.000 claims description 6
- 108010071690 Prealbumin Proteins 0.000 claims description 6
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 6
- 102100038358 Prostate-specific antigen Human genes 0.000 claims description 6
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 6
- 102000007969 Secretagogins Human genes 0.000 claims description 6
- 108010089384 Secretagogins Proteins 0.000 claims description 6
- 108700028909 Serum Amyloid A Proteins 0.000 claims description 6
- 102000054727 Serum Amyloid A Human genes 0.000 claims description 6
- 102100030269 Thioredoxin domain-containing protein 5 Human genes 0.000 claims description 6
- 102000004338 Transferrin Human genes 0.000 claims description 6
- 108090000901 Transferrin Proteins 0.000 claims description 6
- 102000003932 Transgelin Human genes 0.000 claims description 6
- 108090000333 Transgelin Proteins 0.000 claims description 6
- 102000009190 Transthyretin Human genes 0.000 claims description 6
- 102000050760 Vitamin D-binding protein Human genes 0.000 claims description 6
- 101710179590 Vitamin D-binding protein Proteins 0.000 claims description 6
- 102100036643 Zinc finger CCCH domain-containing protein 7B Human genes 0.000 claims description 6
- 108010075843 alpha-2-HS-Glycoprotein Proteins 0.000 claims description 6
- 102000012005 alpha-2-HS-Glycoprotein Human genes 0.000 claims description 6
- 108010073614 apolipoprotein A-IV Proteins 0.000 claims description 6
- 230000002124 endocrine Effects 0.000 claims description 6
- 102000015694 estrogen receptors Human genes 0.000 claims description 6
- 108010038795 estrogen receptors Proteins 0.000 claims description 6
- 108091022862 fatty acid binding Proteins 0.000 claims description 6
- 229940012952 fibrinogen Drugs 0.000 claims description 6
- 108010017007 glucose-regulated proteins Proteins 0.000 claims description 6
- 239000000178 monomer Substances 0.000 claims description 6
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims description 6
- 108010036112 nuclear matrix protein 22 Proteins 0.000 claims description 6
- 108030002458 peroxiredoxin Proteins 0.000 claims description 6
- 239000000600 sorbitol Substances 0.000 claims description 6
- 229960001603 tamoxifen Drugs 0.000 claims description 6
- 239000012581 transferrin Substances 0.000 claims description 6
- 239000002753 trypsin inhibitor Substances 0.000 claims description 6
- 102100022804 BTB/POZ domain-containing protein KCTD12 Human genes 0.000 claims description 5
- 208000032612 Glial tumor Diseases 0.000 claims description 5
- 206010018338 Glioma Diseases 0.000 claims description 5
- 101000974804 Homo sapiens BTB/POZ domain-containing protein KCTD12 Proteins 0.000 claims description 5
- 102000006010 Protein Disulfide-Isomerase Human genes 0.000 claims description 5
- 102100022942 Retinol-binding protein 2 Human genes 0.000 claims description 5
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 5
- 108010011716 cellular retinoic acid binding protein II Proteins 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 108020003519 protein disulfide isomerase Proteins 0.000 claims description 5
- 201000000849 skin cancer Diseases 0.000 claims description 5
- 210000001519 tissue Anatomy 0.000 claims description 5
- 101000577877 Homo sapiens Stromelysin-3 Proteins 0.000 claims description 4
- 102100028847 Stromelysin-3 Human genes 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims description 4
- 229960002986 dinoprostone Drugs 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 238000004949 mass spectrometry Methods 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims description 4
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 3
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims description 3
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 229960004945 etoricoxib Drugs 0.000 claims description 3
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 229960000994 lumiracoxib Drugs 0.000 claims description 3
- KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 claims description 3
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 3
- 201000008968 osteosarcoma Diseases 0.000 claims description 3
- 206010061424 Anal cancer Diseases 0.000 claims description 2
- 208000007860 Anus Neoplasms Diseases 0.000 claims description 2
- 206010004593 Bile duct cancer Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 201000011165 anus cancer Diseases 0.000 claims description 2
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 2
- 229960000590 celecoxib Drugs 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 201000010175 gallbladder cancer Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims description 2
- 201000002314 small intestine cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 229960002004 valdecoxib Drugs 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims 4
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 4
- 206010039491 Sarcoma Diseases 0.000 claims 3
- 208000009956 adenocarcinoma Diseases 0.000 claims 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 3
- 206010003571 Astrocytoma Diseases 0.000 claims 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 2
- 208000018142 Leiomyosarcoma Diseases 0.000 claims 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 2
- 201000005969 Uveal melanoma Diseases 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 201000000053 blastoma Diseases 0.000 claims 2
- 208000035269 cancer or benign tumor Diseases 0.000 claims 2
- 201000008184 embryoma Diseases 0.000 claims 2
- 238000004817 gas chromatography Methods 0.000 claims 2
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 claims 2
- 201000000052 gastrinoma Diseases 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 2
- 208000030883 malignant astrocytoma Diseases 0.000 claims 2
- 201000005962 mycosis fungoides Diseases 0.000 claims 2
- 230000009826 neoplastic cell growth Effects 0.000 claims 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 208000003154 papilloma Diseases 0.000 claims 2
- 208000010626 plasma cell neoplasm Diseases 0.000 claims 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 2
- 208000000649 small cell carcinoma Diseases 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 201000008205 supratentorial primitive neuroectodermal tumor Diseases 0.000 claims 2
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000003200 Adenoma Diseases 0.000 claims 1
- 201000003076 Angiosarcoma Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006143 Brain stem glioma Diseases 0.000 claims 1
- 201000000274 Carcinosarcoma Diseases 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000005171 Cystadenoma Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 208000002249 Diabetes Complications Diseases 0.000 claims 1
- 208000005431 Endometrioid Carcinoma Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 208000017259 Extragonadal germ cell tumor Diseases 0.000 claims 1
- 208000004057 Focal Nodular Hyperplasia Diseases 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 206010018404 Glucagonoma Diseases 0.000 claims 1
- 208000002125 Hemangioendothelioma Diseases 0.000 claims 1
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 1
- 206010019629 Hepatic adenoma Diseases 0.000 claims 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 claims 1
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 claims 1
- 206010061252 Intraocular melanoma Diseases 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- 206010024218 Lentigo maligna Diseases 0.000 claims 1
- 208000036241 Liver adenomatosis Diseases 0.000 claims 1
- 206010025312 Lymphoma AIDS related Diseases 0.000 claims 1
- 208000032271 Malignant tumor of penis Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 206010027193 Meningioma malignant Diseases 0.000 claims 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 206010057269 Mucoepidermoid carcinoma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims 1
- 206010029488 Nodular melanoma Diseases 0.000 claims 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 claims 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 claims 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims 1
- 208000002471 Penile Neoplasms Diseases 0.000 claims 1
- 206010034299 Penile cancer Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 201000008199 Pleuropulmonary blastoma Diseases 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 206010051807 Pseudosarcoma Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000008183 Pulmonary blastoma Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 102000005157 Somatostatin Human genes 0.000 claims 1
- 108010056088 Somatostatin Proteins 0.000 claims 1
- 206010042553 Superficial spreading melanoma stage unspecified Diseases 0.000 claims 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 1
- 206010043276 Teratoma Diseases 0.000 claims 1
- 201000009365 Thymic carcinoma Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046431 Urethral cancer Diseases 0.000 claims 1
- 206010046458 Urethral neoplasms Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 208000009311 VIPoma Diseases 0.000 claims 1
- 206010047741 Vulval cancer Diseases 0.000 claims 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 208000012018 Yolk sac tumor Diseases 0.000 claims 1
- 206010000583 acral lentiginous melanoma Diseases 0.000 claims 1
- 208000009621 actinic keratosis Diseases 0.000 claims 1
- 208000002517 adenoid cystic carcinoma Diseases 0.000 claims 1
- 201000001256 adenosarcoma Diseases 0.000 claims 1
- 201000008395 adenosquamous carcinoma Diseases 0.000 claims 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 claims 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000029336 bartholin gland carcinoma Diseases 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 208000002458 carcinoid tumor Diseases 0.000 claims 1
- 208000030239 cerebral astrocytoma Diseases 0.000 claims 1
- 208000009060 clear cell adenocarcinoma Diseases 0.000 claims 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000001991 endodermal sinus tumor Diseases 0.000 claims 1
- 201000003908 endometrial adenocarcinoma Diseases 0.000 claims 1
- 201000006828 endometrial hyperplasia Diseases 0.000 claims 1
- 201000000330 endometrial stromal sarcoma Diseases 0.000 claims 1
- 208000028730 endometrioid adenocarcinoma Diseases 0.000 claims 1
- 208000029179 endometrioid stromal sarcoma Diseases 0.000 claims 1
- 201000007116 gestational trophoblastic neoplasm Diseases 0.000 claims 1
- 210000004907 gland Anatomy 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 208000030316 grade III meningioma Diseases 0.000 claims 1
- 201000011066 hemangioma Diseases 0.000 claims 1
- 201000006866 hypopharynx cancer Diseases 0.000 claims 1
- 230000002267 hypothalamic effect Effects 0.000 claims 1
- 238000011532 immunohistochemical staining Methods 0.000 claims 1
- 238000013388 immunohistochemistry analysis Methods 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 206010022498 insulinoma Diseases 0.000 claims 1
- 208000003849 large cell carcinoma Diseases 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 208000011080 lentigo maligna melanoma Diseases 0.000 claims 1
- 229950003488 licofelone Drugs 0.000 claims 1
- UAWXGRJVZSAUSZ-UHFFFAOYSA-N licofelone Chemical compound OC(=O)CC=1N2CC(C)(C)CC2=C(C=2C=CC=CC=2)C=1C1=CC=C(Cl)C=C1 UAWXGRJVZSAUSZ-UHFFFAOYSA-N 0.000 claims 1
- 206010024627 liposarcoma Diseases 0.000 claims 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 claims 1
- 201000000966 lung oat cell carcinoma Diseases 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- 208000012804 lymphangiosarcoma Diseases 0.000 claims 1
- 208000006178 malignant mesothelioma Diseases 0.000 claims 1
- 201000000289 malignant teratoma Diseases 0.000 claims 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims 1
- 201000008203 medulloepithelioma Diseases 0.000 claims 1
- 206010027191 meningioma Diseases 0.000 claims 1
- 208000011645 metastatic carcinoma Diseases 0.000 claims 1
- 210000003097 mucus Anatomy 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000001611 myxosarcoma Diseases 0.000 claims 1
- 208000018795 nasal cavity and paranasal sinus carcinoma Diseases 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 201000000032 nodular malignant melanoma Diseases 0.000 claims 1
- 201000002575 ocular melanoma Diseases 0.000 claims 1
- 208000022982 optic pathway glioma Diseases 0.000 claims 1
- 201000006958 oropharynx cancer Diseases 0.000 claims 1
- 208000021284 ovarian germ cell tumor Diseases 0.000 claims 1
- 201000002530 pancreatic endocrine carcinoma Diseases 0.000 claims 1
- 208000021255 pancreatic insulinoma Diseases 0.000 claims 1
- 201000005163 papillary serous adenocarcinoma Diseases 0.000 claims 1
- 208000024641 papillary serous cystadenocarcinoma Diseases 0.000 claims 1
- 208000029211 papillomatosis Diseases 0.000 claims 1
- 208000028591 pheochromocytoma Diseases 0.000 claims 1
- 201000003113 pineoblastoma Diseases 0.000 claims 1
- 208000010916 pituitary tumor Diseases 0.000 claims 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 229960000371 rofecoxib Drugs 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- 210000000582 semen Anatomy 0.000 claims 1
- 208000004548 serous cystadenocarcinoma Diseases 0.000 claims 1
- 210000004872 soft tissue Anatomy 0.000 claims 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims 1
- 229960000553 somatostatin Drugs 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
- 208000030457 superficial spreading melanoma Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 210000001138 tear Anatomy 0.000 claims 1
- 201000000360 urethra cancer Diseases 0.000 claims 1
- 208000037965 uterine sarcoma Diseases 0.000 claims 1
- 206010046885 vaginal cancer Diseases 0.000 claims 1
- 208000013139 vaginal neoplasm Diseases 0.000 claims 1
- 208000008662 verrucous carcinoma Diseases 0.000 claims 1
- 201000005102 vulva cancer Diseases 0.000 claims 1
- 230000008569 process Effects 0.000 abstract description 3
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 62
- 125000004432 carbon atom Chemical group C* 0.000 description 47
- 125000001424 substituent group Chemical group 0.000 description 17
- 125000000217 alkyl group Chemical group 0.000 description 14
- 125000005843 halogen group Chemical group 0.000 description 13
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 10
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 10
- 125000003545 alkoxy group Chemical group 0.000 description 10
- 125000004414 alkyl thio group Chemical group 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 9
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 8
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 8
- 239000002207 metabolite Substances 0.000 description 8
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000011285 therapeutic regimen Methods 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 5
- 150000002066 eicosanoids Chemical class 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 229940114079 arachidonic acid Drugs 0.000 description 4
- 235000021342 arachidonic acid Nutrition 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 108010037464 Cyclooxygenase 1 Proteins 0.000 description 3
- 125000003710 aryl alkyl group Chemical group 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 2
- 241000011102 Thera Species 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 125000005530 alkylenedioxy group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 238000012261 overproduction Methods 0.000 description 2
- 229960004662 parecoxib Drugs 0.000 description 2
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 206010073360 Appendix cancer Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102100037611 Lysophospholipase Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- 102100036201 Oxygen-dependent coproporphyrinogen-III oxidase, mitochondrial Human genes 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 101150109738 Ptger4 gene Proteins 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 208000021780 appendiceal neoplasm Diseases 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 229940110331 bextra Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229940047495 celebrex Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000006041 cell recruitment Effects 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 201000006894 monocytic leukemia Diseases 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 229960000965 nimesulide Drugs 0.000 description 1
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 201000003437 pleural cancer Diseases 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- YIBNHAJFJUQSRA-YNNPMVKQSA-N prostaglandin H2 Chemical compound C1[C@@H]2OO[C@H]1[C@H](/C=C/[C@@H](O)CCCCC)[C@H]2C\C=C/CCCC(O)=O YIBNHAJFJUQSRA-YNNPMVKQSA-N 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000007755 survival signaling Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000013389 whole blood assay Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/88—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/90216—Oxidoreductases (1.) acting on a heme group of donors (1.9)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/17—Nitrogen containing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94947307P | 2007-07-12 | 2007-07-12 | |
| US60/949,473 | 2007-07-12 | ||
| PCT/US2008/069892 WO2009009776A2 (fr) | 2007-07-12 | 2008-07-11 | Sélection de patient et procédés thérapeutiques utilisant des marqueurs du métabolisme de la prostaglandine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2692973A1 true CA2692973A1 (fr) | 2009-01-15 |
Family
ID=40229507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2692973 Abandoned CA2692973A1 (fr) | 2007-07-12 | 2008-07-11 | Selection de patient et procedes therapeutiques utilisant des marqueurs du metabolisme de la prostaglandine |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20120016002A1 (fr) |
| EP (1) | EP2175722A4 (fr) |
| CA (1) | CA2692973A1 (fr) |
| WO (1) | WO2009009776A2 (fr) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9428813B2 (en) | 2012-03-26 | 2016-08-30 | The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services | DNA methylation analysis for the diagnosis, prognosis and treatment of adrenal neoplasms |
| CN111989561A (zh) * | 2018-03-29 | 2020-11-24 | 自动化合作关系（剑桥）有限公司 | 用于生物材料的光谱分析的计算机实现的方法和系统 |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2073010A1 (fr) * | 2007-12-17 | 2009-06-24 | Atlas Antibodies AB | Supports de sélection de traitement du cancer du sein |
| WO2011087869A1 (fr) * | 2009-12-22 | 2011-07-21 | Expression Pathology, Inc. | Dosage srm/mrm de la protéine sécrétée acide et riche en cystéine (sparc) |
| ES2836374T3 (es) | 2014-01-14 | 2021-06-24 | Euclises Pharmaceuticals Inc | Conjugados de nitrooxi-cromeno que liberan NO |
| JP6942726B2 (ja) | 2016-01-08 | 2021-09-29 | ユークリセス ファーマシューティカルズ，インコーポレイテッド | クロメン化合物および第２活性薬剤の併用薬 |
| KR20200018508A (ko) * | 2017-06-12 | 2020-02-19 | 프라운호퍼-게젤샤프트 추르 푀르데룽 데어 안제반텐 포르슝 에 파우 | 프로스타글란딘 E-의존적 종양의 계층화에 대한 바이오마커로서 MiRNA-574-5p |
| WO2021226162A1 (fr) * | 2020-05-05 | 2021-11-11 | Arrys Therapeutics, Inc. | Antagonistes de l'ep4 et leur utilisation dans le traitement des maladies prolifératives" |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5908858A (en) * | 1996-04-05 | 1999-06-01 | Sankyo Company, Limited | 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses |
| AU2003257110A1 (en) * | 2002-07-31 | 2004-02-16 | University Of Southern California | Polymorphisms for predicting disease and treatment outcome |
| US20070213792A1 (en) * | 2002-10-07 | 2007-09-13 | Palomar Medical Technologies, Inc. | Treatment Of Tissue Volume With Radiant Energy |
| US20050107350A1 (en) * | 2003-08-22 | 2005-05-19 | Pharmacia Corporation | Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith |
| WO2005020926A2 (fr) * | 2003-08-28 | 2005-03-10 | Pharmacia Corporation | Traitement ou prevention de troubles vasculaires au moyen d'inhibiteurs de cox-2 associee a des inhibiteurs de la phosphodiesterase specifique de l'amp cyclique |
| US20050187278A1 (en) * | 2003-08-28 | 2005-08-25 | Pharmacia Corporation | Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors |
| WO2005048979A2 (fr) * | 2003-10-06 | 2005-06-02 | Torrent Pharmaceuticals Limited | Composition pharmaceutique avec capsule pour microtablettes multiples |
| US7608416B2 (en) * | 2004-12-07 | 2009-10-27 | The Trustees Of The University Of Pennsylvania | Targeting mPGES-1 as a treatment for inflammation which avoids cardiovascular risk |
-
2008
- 2008-07-11 US US13/130,547 patent/US20120016002A1/en not_active Abandoned
- 2008-07-11 CA CA 2692973 patent/CA2692973A1/fr not_active Abandoned
- 2008-07-11 WO PCT/US2008/069892 patent/WO2009009776A2/fr active Application Filing
- 2008-07-11 EP EP08781744A patent/EP2175722A4/fr not_active Withdrawn
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9428813B2 (en) | 2012-03-26 | 2016-08-30 | The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services | DNA methylation analysis for the diagnosis, prognosis and treatment of adrenal neoplasms |
| CN111989561A (zh) * | 2018-03-29 | 2020-11-24 | 自动化合作关系（剑桥）有限公司 | 用于生物材料的光谱分析的计算机实现的方法和系统 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20120016002A1 (en) | 2012-01-19 |
| EP2175722A2 (fr) | 2010-04-21 |
| WO2009009776A2 (fr) | 2009-01-15 |
| EP2175722A4 (fr) | 2010-08-25 |
| WO2009009776A3 (fr) | 2009-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2692973A1 (fr) | Selection de patient et procedes therapeutiques utilisant des marqueurs du metabolisme de la prostaglandine | |
| Yang et al. | COX-2 in liver fibrosis | |
| Ansari et al. | Pancreatic cancer: yesterday, today and tomorrow | |
| Farrow et al. | Inflammation and the development of pancreatic cancer | |
| Moschen et al. | Adipose and liver expression of interleukin (IL)-1 family members in morbid obesity and effects of weight loss | |
| Hayashi et al. | Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasm | |
| Mifflin et al. | Regulation of COX-2 expression in human intestinal myofibroblasts: mechanisms of IL-1-mediated induction | |
| Derbali et al. | Increased biglycan in aortic valve stenosis leads to the overexpression of phospholipid transfer protein via Toll-like receptor 2 | |
| Mourouzis et al. | Thyroid hormone improves the mechanical performance of the post-infarcted diabetic myocardium: a response associated with up-regulation of Akt/mTOR and AMPK activation | |
| US20200032264A1 (en) | Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels | |
| EP3322980A1 (fr) | Méthodes et compositions pour le diagnostic et le traitement de adrénoleucodystrophie | |
| Shinkai et al. | Intra-articular penetration of ketoprofen and analgesic effects after topical patch application in rats | |
| US20060110786A1 (en) | Compositions and methods for detecting and quantifying COX-2 activity and 2-arachidonylgycerol metabolites | |
| Tanigawa et al. | Rebamipide, a mucoprotective drug, inhibits NSAIDs-induced gastric mucosal injury: possible involvement of the downregulation of 15-hydroxyprostaglandin dehydrogenase | |
| JP2022119827A (ja) | Ｓ－アデノシルメチオニンの類似体を用いたｓ－アデノシルメチオニンのイムノアッセイおよび個別化治療法 | |
| EP2854865A2 (fr) | Méthodes de traitement d'un syndrome métabolique par modulation de la protéine de choc thermique (hsp) 90-bêta | |
| Lei et al. | The lipid peroxidation product EKODE exacerbates colonic inflammation and colon tumorigenesis | |
| Wanninger et al. | Adiponectin induces the transforming growth factor decoy receptor BAMBI in human hepatocytes | |
| Zhan et al. | Intestinal fibrosis and gut microbiota: clues from other organs | |
| WO2013074583A1 (fr) | Traitement et pronostic d'une lymphangioleimyomatose | |
| Du et al. | Targeting NFATc4 attenuates non-alcoholic steatohepatitis in mice | |
| Nørregaard et al. | Cyclooxygenase type 2 is increased in obstructed rat and human ureter and contributes to pelvic pressure increase after obstruction | |
| Li et al. | Measurement of serum and hepatic eicosanoids by liquid chromatography tandem-mass spectrometry (LC-MS/MS) in a mouse model of hepatocellular carcinoma (HCC) with delivery of c-Met and activated β-catenin by hepatocyte hydrodynamic injection | |
| Robbins et al. | Increased levels of prostaglandin D2 suggest macrophage activation in patients with primary pulmonary hypertension | |
| Kuefner et al. | Decreased histamine catabolism in the colonic mucosa of patients with colonic adenoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20130711 |